PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
• PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
A. PIPELINE
PART 06: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• SCIT – Market size and forecast 2018-2023
• SLIT – Market size and forecast 2018-2023
• Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• EMEA – Market size and forecast 2018-2023
• Americas – Market size and forecast 2018-2023
• APAC – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• ALK
• Allergy Therapeutics
• HAL Allergy
• Merck
• Stallergenes Greer
PART 14: APPENDIX
• Research methodology
• List of abbreviations
PART 15: EXPLORE TECHNAVIO
Exhibit 01: Global immunology treatment market
Exhibit 02: Segments of global immunology treatment market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition – Inclusions and exclusions checklist
Exhibit 06: Global allergy immunotherapies market: Overview
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2018
Exhibit 18: Global allergy immunotherapies market pipeline: Overview
Exhibit 19: Global allergy immunotherapies market pipeline: Overview
Exhibit 20: Product – Market share 2018-2023 (%)
Exhibit 21: Comparison by product
Exhibit 22: SCIT – Market size and forecast 2018-2023 ($ millions)
Exhibit 23: SCIT – Year-over-year growth 2019-2023 (%)
Exhibit 24: Opportunity analysis of global SCIT market
Exhibit 25: SLIT – Market size and forecast 2018-2023 ($ millions)
Exhibit 26: SLIT – Year-over-year growth 2019-2023 (%)
Exhibit 27: Opportunity analysis of global SLIT market
Exhibit 28: Market opportunity by product
Exhibit 29: Customer landscape
Exhibit 30: Market share by geography 2018-2023 (%)
Exhibit 31: Geographic comparison
Exhibit 32: EMEA – Market size and forecast 2018-2023 ($ millions)
Exhibit 33: EMEA – Year-over-year growth 2019-2023 (%)
Exhibit 34: Americas – Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Americas – Year-over-year growth 2019-2023 (%)
Exhibit 36: APAC – Market size and forecast 2018-2023 ($ millions)
Exhibit 37: APAC – Year-over-year growth 2019-2023 (%)
Exhibit 38: Key leading countries
Exhibit 39: Market opportunity
Exhibit 40: Impact of drivers and challenges
Exhibit 41: Vendor landscape
Exhibit 42: Landscape disruption
Exhibit 43: Geographical presence of few prominent vendors 2018
Exhibit 44: Vendors covered
Exhibit 45: Vendor classification
Exhibit 46: Market positioning of vendors
Exhibit 47: ALK – Vendor overview
Exhibit 48: ALK – Business segments
Exhibit 49: ALK – Organizational developments
Exhibit 50: ALK – Geographic focus
Exhibit 51: ALK – Key offerings
Exhibit 52: ALK – Key customers
Exhibit 53: Allergy Therapeutics – Vendor overview
Exhibit 54: Allergy Therapeutics – Business segments
Exhibit 55: Allergy Therapeutics – Organizational developments
Exhibit 56: Allergy Therapeutics – Segment focus
Exhibit 57: Allergy Therapeutics – Key offerings
Exhibit 58: Allergy Therapeutics – Key customers
Exhibit 59: HAL Allergy – Vendor overview
Exhibit 60: HAL Allergy – Business segments
Exhibit 61: HAL Allergy – Organizational developments
Exhibit 62: HAL Allergy – Key offerings
Exhibit 63: HAL Allergy – Key customers
Exhibit 64: Merck – Vendor overview
Exhibit 65: Merck – Business segments
Exhibit 66: Merck – Organizational developments
Exhibit 67: Merck – Geographic focus
Exhibit 68: Merck – Segment focus
Exhibit 69: Merck – Key offerings
Exhibit 70: Merck – Key customers
Exhibit 71: Stallergenes Greer – Vendor overview
Exhibit 72: Stallergenes Greer – Business segments
Exhibit 73: Stallergenes Greer – Organizational developments
Exhibit 74: Stallergenes Greer – Geographic focus
Exhibit 75: Stallergenes Greer – Key offerings
Exhibit 76: Stallergenes Greer – Key customers
【掲載企業】
ALK、Allergy Therapeutics、HAL Allergy、Merck、Stallergenes Greer